Multiple Myeloma Lesion Detection With Whole Body CT Versus Radiographic Skeletal Survey

REFERENCES

• Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics. CA Cancer J Clin 2011;61:212–236.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–854.
   PubMed Web of Science ®Google Scholar
• Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379–398.
   PubMedGoogle Scholar
• Durie B. The role of anatomic and functional imaging in myeloma: description of Durie/Salmon PLUS staging system. Eur J Cancer 2006;42:1539–1543.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23:1545–1556.
   PubMed Web of Science ®Google Scholar
• Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, Wendtner C, Bachner F, Reiser M. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334–1345.
   PubMed Web of Science ®Google Scholar
• Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007;109:1617–1626.
   PubMed Web of Science ®Google Scholar
• Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, McHugh J, O'Connell M, O'Gorman P, Eustace SJ. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2009; 38:225–236.
   PubMed Web of Science ®Google Scholar
• Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Metha A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133–135.
   PubMed Web of Science ®Google Scholar
• Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR 2005;184:1199–1204.
   PubMed Web of Science ®Google Scholar
• Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–1463.
   PubMed Web of Science ®Google Scholar
• Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA J Am Med Assoc 2003;290:3199–3206.
   PubMed Web of Science ®Google Scholar
• Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Rad 2005;55:56–63.
   PubMed Web of Science ®Google Scholar
• Breyer R, Mulligan ME, Smith S, Line B, Badros A. Comparison of FDG PET/CT to other imaging modalities in myeloma. Skeletal Radiol 2006 Sept;35(9):632–640.
   PubMed Web of Science ®Google Scholar
• Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, Günther RW. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178:1429–1436.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606–1610.
   PubMed Web of Science ®Google Scholar
• Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121–1128.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94:57–61.
   PubMed Web of Science ®Google Scholar
• He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev. 2003; CD004023.
   PubMedGoogle Scholar